within Pharmacolibrary.Drugs.ATC.S;

model S01GX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.427 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.036899999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Epinastine is a second-generation antihistamine with selective H1 receptor antagonist and mast cell stabilizing properties. It is primarily used for the treatment of allergic conjunctivitis and is approved for ophthalmic use in many countries.</p><h4>Pharmacokinetics</h4><p>No dedicated peer-reviewed pharmacokinetic model publications are available for epinastine, especially for the ophthalmic (topical eye drop) route, which is the most common clinical use. Available data are limited to some brief reports and drug monographs, mainly based on healthy adult subjects.</p><h4>References</h4><ol><li><p>Trattler, WB, et al., &amp; Majmudar, P (2006). Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis. <i>International ophthalmology clinics</i> 46(4) 87–99. DOI:<a href=&quot;https://doi.org/10.1097/01.iio.0000212136.77675.b1&quot;>10.1097/01.iio.0000212136.77675.b1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17060795/&quot;>https://pubmed.ncbi.nlm.nih.gov/17060795</a></p></li><li><p>Mochizuki, T, et al., &amp; Mano, H (2024). Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits. <i>Japanese journal of ophthalmology</i> 68(5) 594–602. DOI:<a href=&quot;https://doi.org/10.1007/s10384-024-01070-6&quot;>10.1007/s10384-024-01070-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38795193/&quot;>https://pubmed.ncbi.nlm.nih.gov/38795193</a></p></li><li><p>Minami, T, et al., &amp; Yamagami, S (2019). In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses. <i>PloS one</i> 14(1) e0210362–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0210362&quot;>10.1371/journal.pone.0210362</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30699147/&quot;>https://pubmed.ncbi.nlm.nih.gov/30699147</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01GX10;
